PMC

Pharmedic (PMC) has been ordered by the Drug Administration of Vietnam to recall a batch of sodium chloride 0.9% eye drops nationwide due to clarity non-compliance (level 3 violation). The company, generating ~VND 500B in annual revenue, was previously fined VND 70M for a separate drug quality issue. This marks a second quality incident in two years, raising regulatory and reputational risks for the firm.

PMC faces a nationwide recall of its Natri clorid 0.9% eye drop after failing clarity standards, classified as a level 3 violation. The stock fell nearly 1% on May 15, recovering from an intraday drop of 10%, though liquidity remains thin. The incident follows a VND 70 million fine in January for similar quality issues.

PMC, the HNX-listed pharmaceutical firm, saw its stock drop nearly 10% after a nationwide recall of its Natri clorid 0.9% eye drop product due to a clarity quality failure. The recall, ordered by the Lam Dong Department of Health, affects a single batch and is classified as a Level 3 violation. While the financial impact appears limited, the event adds pressure on a stock already in a downtrend from its December 2025 peak.

PMC had a batch of Natri clorid 0.9% eye drops recalled nationwide by the Drug Administration of Vietnam for failing quality standards (clarity index). The stock dropped 0.72% on the day and has lost 33% from its December 2025 peak. The company previously paid a 70 million VND fine for similar violations, raising governance concerns.